drugset
drugset / Trial / NCT04336449

Eptinezumab in Healthy Japanese Subjects

NCT04336449 ↗

Phase 1 Completed 18 enrolled H. Lundbeck A/S
RandomizedSequentialDouble-blindTreatment

Summary

The purpose of this study is to investigate how eptinezumab enters, moves through and exits the body. Safety and tolerability will also be investigated.

Timeline

Start
2020-04-01
Primary completion
2020-08-13
Completion
2020-08-13

Drugs

EvaluationDrugModalityDoseRoute
Subject Eptinezumab Monoclonal antibody 100 mg Intravenous
Subject Eptinezumab Monoclonal antibody 300 mg Intravenous

Indications

No indication recorded.